Management Impact of Metachronous Oligometastatic Disease Identified on 18 F-Fluciclovine (Axumin™) PET/CT in Biochemically Recurrent Prostate Cancer.

F-fluciclovine PET/CT for imaging evaluation of BCR was 23.6% in our eligible patient population. There was no significant association between serum PSA level and the number of oligometastases. Treatment management was affected in 57.1% of patients with oligometastases.